Introduction: The present study aimed to inform an economic evaluation of dabrafenib
INTRODUCTION
has demonstrated consistent activity against melanoma in pretreated and chemotherapy-naïve patients [1] [2] [3] . More recently, two novel anti-PD-1 immune checkpoint inhibitors, pembrolizumab and nivolumab, have been approved based on randomized controlled trials demonstrating improved outcomes versus ipilimumab alone [4] [5] [6] .
Dysregulation of BRAF signaling in the MAPK pathway is a key driver of metastatic melanoma [7] . Two inhibitors of the BRAF protein, vemurafenib and dabrafenib, have been approved for treatment of patients with BRAF V600 mutation-positive unresectable stage IIIC or stage IV (advanced or metastatic) melanoma.
These approvals were based on the results of the BRIM-3 (ClinicalTrials.gov identifier:
NCT01006980) and BREAK-3 (ClinicalTrials.gov identifier: NCT01227889) randomized controlled trials, respectively, which demonstrated improved outcomes versus dacarbazine (DTIC) in front-line treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma [8] [9] [10] [11] [12] [13] [14] . Trametinib is a highly potent and selective small-molecule inhibitor of the MEK kinase that is downstream of and activated by BRAF in the MAPK pathway.
Trametinib has been shown to be more effective than chemotherapy in treatment-naïve or previously treated patients with BRAF V600 mutation-positive unresectable or metastatic melanoma [15] . These results, as well as improved understanding of the mechanisms of resistance to targeted therapies, have led to the exploration of combination approaches to targeted therapy. The efficacy and safety of dabrafenib in combination with trametinib has been evaluated in two phase 3 trials, the COMBI-d (ClinicalTrials.gov identifier:
NCT01584648) and COMBI-v (ClinicalTrials.gov identifier: NCT01597908) trials, as well as the phase 2 BRF113220 (ClinicalTrials.gov identifier: NCT01072175) trial [16] [17] [18] [19] [20] [21] . Results of these trials have demonstrated that dabrafenib plus trametinib improves progression-free survival (PFS) and overall survival (OS) compared with dabrafenib monotherapy or vemurafenib monotherapy treatment-naïve patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. Trials included in the analysis were identified from two systematic literature reviews. Details regarding the reviews have been published previously [22, 23] . Both reviews followed the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines [24] . The first review was undertaken to evaluate efficacy, safety, and tolerability of dabrafenib and trametinib monotherapy versus other first-line treatments for unresectable advanced or metastatic melanoma [22] . The second review was undertaken to evaluate the efficacy and safety of the dabrafenib plus trametinib therapy compared to other first-line or second-line treatments for patients with unresectable or metastatic melanoma [23] . For both reviews, HRs for PFS and OS were based on analyses of the most recent data cuts available from each trial at the time the evaluation was completed [9, 13, 15, 16, 18, 20, 25] . HRs for PFS and OS from the METRIC trial were based on analyses of the first-line subgroup. HRs for OS from the BRIM-3, BREAK-3, METRIC, and BRF113220 trials were based on Rank Preserving Structural Failure Time (RPSFT) analyses to adjust for crossover from control to active therapy [10, 14, 26, 27] . HRs for PFS and OS for ipilimumab were based on results of the CA184-024 trial [25] . Although this trial included both BRAF mutation-positive and BRAF wild-type patients, it was the only study available at the time of the analysis that reported both PFS and OS for ipilimumab as first-line treatment of metastatic melanoma. Also, although the approved dosage for ipilimumab is 3 mg/kg q3w as monotherapy, this trial compared ipilimumab 10 mg/kg plus DTIC versus DTIC. In the economic evaluation which this analysis informed, results for ipilimumab 10 mg/kg plus DTIC were used to estimate outcomes for patients receiving the approved dosage.
HRs were estimated by Bayesian network meta-analysis using WinBUGS 1.4.3Ó (MRC Biostatistics Unit, Cambridge, UK) with input data taking the form of the log transformed HRs from each trial and the corresponding standard errors [28] . For each comparison, the log HRs for PFS and OS were estimated alternatively using multivariate network meta-analysis (in which treatment effects on PFS and OS were estimated simultaneously) and using traditional or univariate network meta-analysis (in which the analyses of PFS and OS were conducted separately). A multivariate network meta-analysis uses the correlation of the HRs for PFS and OS in the network to inform parameter estimation [29] . The use of this approach is reasonable given the well-established correlation between treatment effects on PFS and OS in metastatic melanoma [30] .
Given the small number of trials with which to estimate random effects (in the analysis assuming no class effect for BRAF inhibitors, there was only one comparison for which there was more than one trial to estimate the random effects), a fixed effects model was employed.
Model parameters were estimated using the WinBUGS software package (version 1.43) Study design and patient characteristics are reported in Table 1 . COMBI-v was the largest trial; BRF113220 was the smallest. Mean age ranged from 49 years (BRF113220, dabrafenib plus trametinib 1 mg) to 58 years (BRF113220, dabrafenib plus trametinib 2 mg). The percent male ranged from 49% (METRIC, DTIC) to 63% (BRF113220, dabrafenib plus trametinib 2 mg). The percent with Eastern Cooperative Oncology Group performance status[0 ranged from 25% (COMBI-d, dabrafenib plus trametinib) to 37% (BRF113220, dabrafenib). The percent with stage M1C at diagnosis ranged from 55% (CA184-024, DTIC) to 70% (BRF113220, dabrafenib plus trametinib 2 mg). The percent with elevated lactate dehydrogenase ranged from 30% (BREAK-3, DTIC) to 58% (BRIM-3, DTIC).
HRs used in the network meta-analyses are shown in Table 2 . The HRs for PFS for the research arm versus the control arm were statistically significant for all trials. The HR for OS for the research arm versus the control arm was statistically significant for COMBI-v, COMBI-d, BRIM-3, and CA184-024. Note that the HRs for OS for BREAK-3, BRIM-3, METRIC, and BRF113220 are based on RPSFT analyses that adjust for crossover from control to active therapy. The 95% CIs for these HRs are therefore relatively wide compared to those in other trials.
Results of the network meta-analysis on HRs for PFS and OS for the analysis assuming no class-effect for BRAF inhibitors are shown in Table 3 Results of the network meta-analysis on HRs for PFS and OS for the analysis assuming a class-effect for BRAF inhibitors are shown in Fig. 3 . These results were generally similar to those for the analysis in which separate HRs were estimated for dabrafenib and vemurafenib monotherapy. When all trials and treatments HR hazard ratio, PFS progression-free survival, OS overall survival, DTIC dacarbazine, RPSFT rank preserving structural failure time a The reported confidence interval for the RPSFT adjusted HR for OS for BRIM-3 (HR = 0.64, 95% CI 0.53-0.78) implied a lower p value than that from the intent-to-treat analysis (HR = 0.76, 95% CI 0.63-0.93). Since the RPSFT method does not increase statistical power, the reported confidence interval was assumed to be erroneous. The confidence interval used in the analysis was obtained by solving for the standard error on the log(HR) which yielded the same p value as the corresponding intent-to-treat analysis b First-line subgroup of primary efficacy population The results for dabrafenib-trametinib were more favorable compared with trametinib and ipilimumab plus DTIC when HRs for PFS and OS were estimated using multivariate network meta-analysis to account for the correlation of treatment effects on PFS and OS than when they were estimated separately using traditional univariate network meta-analysis. Results were generally similar when it was assumed there was a class effect on PFS and OS for BRAF inhibitor monotherapy compared with analyses in which no such assumption was made. Results also were similar when the phase 2 BRF113220 trial was included or excluded.
A targeted search identified several network meta-analyses of treatments for metastatic melanoma [22, [31] [32] [33] [34] . Two of these articles focused on comparisons of chemotherapies and interferon [32, 33] . One study focused on comparisons of ipilimumab versus immunotherapies, chemotherapies, and biochemotherapies, but did not consider BRAF or MEK inhibitors [34] . Srivastava and colleagues conducted a systematic review and indirect treatment comparison of dabrafenib and trametinib as monotherapy versus other treatments in previously untreated metastatic melanoma patients; this study did not include BRAF-MEK combination therapy, however [22] .
Only one study was identified that included dabrafenib plus trametinib [31] . This study by Regarding the assumption that the efficacy of ipilimumab 10 mg/kg is equivalent to 3 mg/ kg, the CA184-004 trial compared ipilimumab 3 versus 10 mg/kg in a mixed population of 101 melanoma patients with and without prior treatment. There was no evidence of improved PFS or OS with 10 versus 3 mg/kg in this trial [37, 38] . The CA184-022 trial compared 0.3, 3, and 10 mg/kg in 214 previously treated patients with melanoma [39, 40] 
